-
鼻咽癌(nasopharyngeal carcinoma,NPC)是一种头颈部常见恶性肿瘤,国际癌症研究机构数据显示,2018年全球新增NPC病例约有12.9万例,约占全年诊断出的所有癌症的0.7%,早期NPC病人的主要治疗方法是放射治疗[1-3]。晚期病人国家综合癌症网络(National Comprehensive Cancer Network,NCCN)指南建议放化疗和辅助化疗或诱导化疗联合治疗[4]。研究[5]表明,晚期病人10年总生存率低于50%,经联合治疗的Ⅲ~ⅣA~B期病人30%以上发生远处转移,这也是鼻咽癌NPC病人致死的主要原因。电压门控钠离子通道β4亚基(SCN4B/β4)是钠离子通道的阻遏蛋白,也是一种细胞黏附分子,对细胞聚集、浸润、迁移等有作用[6]。BON等[7]发现在乳腺癌组织中SCN4B/β4对肿瘤细胞侵袭发挥作用。目前对SCN4B/β4在NPC组织中的表达与预后的关系尚未见相关报道,本研究检测SCN4B/β4在NPC组织中的表达, 分析其与临床因素和预后的相关性,为寻找NPC预后生物标志物提供依据。
-
免疫组织化学结果显示,与对照组相比,SCN4B/β4蛋白在癌组织中的表达明显下调(见图 1);SCN4B/β4蛋白在对照组中高表达率为85.0%(17/20),在NPC组织中高表达率为30.0%(27/90),差异有统计学意义(χ2=19.31,P < 0.01)。
-
SCN4B/β4蛋白在不同性别、年龄NPC中的表达差异无统计学意义(P>0.05)。SCN4B/β4蛋白表达在不同T分期、N分期、M分期、临床分期差异有统计学意义(P < 0.05~P < 0.01),T1~T2期、M0期、Ⅰ~Ⅱ期SCN4B/β4蛋白高表达率高于T3~T4分期、M1分期和Ⅲ~Ⅳ期,随N分期增加,SCN4B/β4蛋白高表达率下降(见表 2)。SCN4B/β4蛋白表达与局部浸润、淋巴结转移、远处转移和临床分期有相关性(P < 0.05)(见表 3)。
临床特征 n SCN4B/β4蛋白 χ2 P 高表达 低表达 年龄/岁 ≤50
>5048
4212(25.0)
15(35.7)36(75.0)
27(64.3)1.22 >0.05 性别 男
女51
3913(25.5)
14(35.9)38(74.5)
25(64.1)1.14 >0.05 T分期 T1~T2
T3~T444
4618(40.9)
9(19.6)26(59.1)
37(80.4)4.88 < 0.05 N分期 N0 30 13(43.3) 17(56.7) N1
N218
247(38.9)
6(25.0)11(61.1)
18(75.0)2.80* < 0.01 N3 18 1(5.6) 17(94.4) M分期 M0
M171
1925(35.2)
2(10.5)46(64.8)
17(89.5)4.35 < 0.05 临床分期 Ⅰ~Ⅱ期
Ⅲ~Ⅳ期33
5717(51.5)
10(17.5)16(48.5)
47(82.5)11.47 < 0.01 *示Zc值 表 2 SCN4B/β4蛋白表达与临床因素之间相关性[n;百分率(%)]
项目 SCN4B/β4蛋白 r P T分期(局部浸润) 0.233 < 0.05 N分期(淋巴结转移) 0.296 < 0.01 M分期(远处转移) 0.220 < 0.05 临床分期 0.357 < 0.01 表 3 SCN4B/β4蛋白表达水平相关性分析
-
2017年6月至2019年7月进行电话随访,分析病人5年生存率。5年的总生存(OS)率为67.8%,临床Ⅰ期为94.4%,Ⅱ期为93.3%,Ⅲ期为81.5%,Ⅳ期为30.0%(见图 2A)。SCN4B/β4高表达生存率为85.2%,SCN4B/β4低表达5年生存率为60.3%,高表达SCN4B/β4病人的5年OS率高于低表达SCN4B/β4病人(χ2=5.35,P < 0.05)(见图 2B)。
SCN4B/β4在鼻咽癌组织中的表达及意义
Expression and significance of SCN4B/β4 in nasopharyngeal carcinoma tissue
-
摘要:
目的探讨电压门控钠离子通道β4亚基(SCN4B/β4)在鼻咽癌组织中的表达,并分析其临床意义。 方法应用免疫组织化学ElivisionTM Plus法检测90例鼻咽癌病人鼻咽部活检标本和20份存档的石蜡包埋正常鼻咽黏膜组织(主要为鼻咽黏膜慢性炎)标本的SCN4B/β4表达情况,分析SCN4B/β4的阳性表达与鼻咽癌病人临床病理特征的关系。 结果鼻咽癌病人SCN4B/β4蛋白表达率低于正常鼻咽黏膜组织病人(P < 0.01);SCN4B/β4蛋白表达在不同T分期、N分期、M分期、临床分期差异有统计学意义(P < 0.05~P < 0.01),T1~T2期、M0期、Ⅰ~Ⅱ期SCN4B/β4蛋白高表达率高于T3~T4分期、M1分期和Ⅲ~Ⅳ期,随N分期增加,SCN4B/β4蛋白高表达率下降;SCN4B/β4高表达5年生存率为85.2%,高于SCN4B/β4低表达的60.3%(P < 0.05)。 结论鼻咽癌组织的SCN4B/β4蛋白高表达与淋巴结和远处转移呈负相关,SCN4B/β4高表达病人生存率较高。 -
关键词:
- 鼻咽肿瘤 /
- 电压门控钠离子通道β4亚基 /
- 预后
Abstract:ObjectiveTo explore the expression level of voltage-gated sodium channel β4 subunit(SCN4B/β4) in nasopharyngeal carcinoma tissue, and analyze its clinical significance. MethodsThe expression levels of SCN4B/β4 in 90 nasopharyngeal biopsy specimens from nasopharyngeal carcinoma patients and 20 archived paraffin-embedded normal nasopharyngeal mucosal tissues(mainly chronic inflammation of nasopharyngeal mucosa) were detected using the ElivisionTM Plus immunohistochemical method.The relationship between the positive expression of SCN4B/β4 and clinicopathological features in patients with nasopharyngeal carcinoma were analyzed. ResultsThe expression rate of SCN4B/β4 protein in nasopharyngeal carcinoma tissue was lower than that in normal nasopharyngeal mucosa(χ2=19.31, P < 0.01).The differences of the expression levels of SCN4B/β4 protein in different T stage, N stage, M stage and clinical stage were statistically significant(P < 0.05 to P < 0.01), the expression rates of SCN4B/β4 protein in stageT1-T2, M0, Ⅰ-Ⅱwere higher than that in stage T3-T4, M1 and Ⅲ-Ⅳ, and the expression rate of SCN4B/β4 protein decreased with the increasing of N stage.The survival rate of patients with high SCN4B/β4 expression was 85.2%, the survival rate of patients with low SCN4B/β4 expression was 60.3%, and the 5-year overall survival rate in patients with high expression of SCN4B/β4 was higher than that in patients with low SCN4B/β4 expression(χ2=5.35, P < 0.05). ConclusionsThe expression level of SCN4B/β4 protein in nasopharyngeal carcinoma is negatively correlated with the lymph node and distant metastasis.The survival rate in patients with high SCN4B/β4 expression is higher. -
表 2 SCN4B/β4蛋白表达与临床因素之间相关性[n;百分率(%)]
临床特征 n SCN4B/β4蛋白 χ2 P 高表达 低表达 年龄/岁 ≤50
>5048
4212(25.0)
15(35.7)36(75.0)
27(64.3)1.22 >0.05 性别 男
女51
3913(25.5)
14(35.9)38(74.5)
25(64.1)1.14 >0.05 T分期 T1~T2
T3~T444
4618(40.9)
9(19.6)26(59.1)
37(80.4)4.88 < 0.05 N分期 N0 30 13(43.3) 17(56.7) N1
N218
247(38.9)
6(25.0)11(61.1)
18(75.0)2.80* < 0.01 N3 18 1(5.6) 17(94.4) M分期 M0
M171
1925(35.2)
2(10.5)46(64.8)
17(89.5)4.35 < 0.05 临床分期 Ⅰ~Ⅱ期
Ⅲ~Ⅳ期33
5717(51.5)
10(17.5)16(48.5)
47(82.5)11.47 < 0.01 *示Zc值 表 3 SCN4B/β4蛋白表达水平相关性分析
项目 SCN4B/β4蛋白 r P T分期(局部浸润) 0.233 < 0.05 N分期(淋巴结转移) 0.296 < 0.01 M分期(远处转移) 0.220 < 0.05 临床分期 0.357 < 0.01 -
[1] BRAY F, FERLAY J, SOERJOMATARAM I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2018, 68(6): 394. doi: 10.3322/caac.21492 [2] FERLAY J, ERVIK M, LAM F, et al. Global Cancer Observatory: cancer today[M]. Lyon, France: International Agency for Research on Cancer, 2018. [3] BLANCHARD P, LEE A, MA RGUET S, et al. Chemotherapy and radiotherapy in nasopharyngeal carcinoma: an update of the MAC-NPC meta-analysis[J]. Lancet Oncol, 2015, 16(6): 645. doi: 10.1016/S1470-2045(15)70126-9 [4] COLEVAS AD, YOM SS, PFISTER DG, et al. NCCN guidelines insights: head and neck cancers, version 1[J]. J Natl Compr Canc Netw, 2018, 16(5): 479. doi: 10.6004/jnccn.2018.0026 [5] HUANG PY, ZENG Q, CAO KJ, et al. Ten-year outcomes of a randomised trial for locoregionally advanced nasopharyngeal carcinoma: a single-institution experience from an endemicarea[J]. Eur J Cancer, 2015, 51(13): 1760. doi: 10.1016/j.ejca.2015.05.025 [6] PATINO GA, ISOM LL. Electrophysiology and beyond: multi-ple roles of Na+ channel β subunits in development and disease[J]. Neurosci Lett, 2010, 486(2): 53. doi: 10.1016/j.neulet.2010.06.050 [7] BON E, DRIFFORT V, GRADEK F, et al. SCN4B acts as a metastasis-suppressor gene preventing hyperactivation of cell migration in breast cancer[J]. Nat Commun, 2016, 7: 13648. doi: 10.1038/ncomms13648 [8] 杨军, 康安静, 苏宝山, 等. 免疫组织化学检测结果判读进展[J/CD]. 中华临床医师杂志(电子版), 2014, 8(20): 3699. [9] TEO PM, LEUNG SF, YU P, et al. A comparison of Ho's, International Union Against Cancer, and American Joint Committee stage classifications for nasopharyngeal carcinoma[J]. Cancer, 1991, 67(2): 434. doi: 10.1002/1097-0142(19910115)67:2<434::AID-CNCR2820670219>3.0.CO;2-A [10] NAMADURAI S, YEREDDI NR, CUSDIN FS, et al. A new look at sodium channel β subunits[J]. Open Biol, 2015, 5(1): 140192. doi: 10.1098/rsob.140192 [11] SHIMIZU H, TOSAKI A, OHSAWA N, et al. Parallel homodimer structures of the extracellular domains of the voltage-gated soadium channe/B4 subunit explain its role in cell-cell adhesion[J]. J Biol Chem, 2017, 292(32): 13428. doi: 10.1074/jbc.M117.786509 [12] MASSAGUE J, BATLLE E, GOMIS RR. Understanding the molecular mechanisms adriving metastasis[J]. Mol Oncol, 2017, 11(1): 3. doi: 10.1002/1878-0261.12024 [13] KAUSHIK N, KIM S, SUH Y, et al. Proinvasive extracellular matrix remodeling for tumor progression[J]. Arch Pharm Res, 2019, 42(1): 40. doi: 10.1007/s12272-018-1097-0 [14] LIM EJ, SUH Y, KIM S, et al. Force-mediated proinvasive matrix remodeling driven by tumor-associated mesenchymal stem-like cells in glioblastoma[J]. BMB Rep, 2018, 51(4): 182. doi: 10.5483/BMBRep.2018.51.4.185 [15] GONG Y, YANG J, WU W, et al. Preserved SCN4B expression is an independent indicator of favorable recurrence-free survival in classical papillary thyroid cancer[J]. PLoS One, 2018, 13(5): e0197007. doi: 10.1371/journal.pone.0197007